Decipher, Polaris and Oncotype in prostate cancer – pro
It is now mentioend by NCCN which is supportive since 2024 and otehr guideliens.
American Association of Clinical Urologists, Inc. (AACU) website. Position
statement: genomic testing in prostate cancer. Available at: https://aacuweb.org/
wp-content/uploads/2022/02/Position-Statement-Tissue-based-genetic-testing-
in-prostate-cancer-Endorsement-02-26-18.pdf
Eggener SE, Rumble RB, Armstrong AJ, et al. Molecular biomarkers in localized
prostate cancer: ASCO Guideline. J Clin Oncol. 2020;38(13):1474-1494. doi:
10.1200/JCO.19.02768
Eastham JA, Auffenberg GB, Barocas DA et al: Clinically localized prostate
cancer: AUA/ASTRO guideline part I: introduction, risk assessment, staging and
risk-based management. J Urol. 2022;208(1):10-18. doi:
10.1097/JU.0000000000002757. Epub 2022 May 10
Schaeffer EM, Srinivas S, Adra A, et al. National Comprehensive Cancer
Network (NCCN) Guidelines Version 4.2024 – May 17, 2024. Prostate Cancer.
Available at: https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf
Referenced with permission from the NCCN Clinical Practice Guidelines in
Oncology (NCCN Guidelines®) for Prostate cancer V4.2024 – May 17, 2024.
©2024 National Comprehensive Cancer Network, Inc. ,
Wagner J, et al “Prostate cancer genomics: Comparing Decipher, Prolaris, and Oncotype DX Results” AUA 2018; Abstract PD06-09.